ImageneBio posts Q3 2025 results via press release

ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/12/2025 - 07:25 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results through a press release dated November 12, 2025, which is included as an exhibit to the report.

The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the federal securities laws. ImageneBio’s common stock trades on The Nasdaq Capital Market under the symbol IMA.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImageneBio (IMA) disclose in this Form 8-K?

ImageneBio disclosed that it announced financial results for the quarter ended September 30, 2025, via a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to the report.

Which period do ImageneBio’s newly announced results cover?

The results cover ImageneBio’s financial performance for the quarter ended September 30, 2025. These quarterly results are summarized in a press release furnished as Exhibit 99.1 to the Form 8-K.

How did ImageneBio (IMA) release its Q3 2025 financial results?

ImageneBio released its Q3 2025 financial results through a press release dated November 12, 2025. That press release is attached to the Form 8-K as Exhibit 99.1 and is furnished, not filed.

Is ImageneBio’s earnings press release considered filed with the SEC?

No. The company states the earnings press release in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, limiting related liability treatment.

Who signed ImageneBio’s November 12, 2025 Form 8-K?

The Form 8-K was signed on behalf of ImageneBio, Inc. by Kristin Yarema, Ph.D., the company’s Chief Executive Officer, on November 12, 2025, as the duly authorized officer.

On which exchange is ImageneBio (IMA) common stock listed?

ImageneBio’s common stock, with a par value of $0.001 per share, is listed for trading on The Nasdaq Capital Market under the ticker symbol IMA, according to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASDAQ false 0001835579 0001835579 2025-11-12 2025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 12, 2025, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release Dated November 12, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: November 12, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer